CAR-T Cell Therapy Compared With Stem Cell Transplant for Multiple Myeloma
Compares CAR-T cell therapy with stem cell transplant in newly diagnosed multiple myeloma patients.
Plain-language title generated from the registry record
Registry title: BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06793449, who can take part
Where in China
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT06793449
- Record updated
- 3 August 2025
- Original description
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.Read full original descriptionShow less
A Prospective, Non-inferiority Study Comparing VRD±D Followed by BCMA CAR-T Cell Therapy Versus VRD±D Followed by Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Patients With Newly-diagnosed Multiple Myeloma
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.
Inclusion: Be informed and voluntarily sign the Informed Consent Form (ICF); Age between 18 and 70 years (inclusive); Have measurable disease meeting at least one of the following criteria: Serum M-protein ≥1 g/dL (>10 g/L) as detected by serum protein electrophoresis (SPEP), or quantifiable IgA or IgD levels for IgA or IgD-type myeloma; Urine M-protein ≥200 mg/24 hours; In cases where serum and urine M-protein do not meet the above thresholds, an abnormal free light chain (FLC) ratio (normal range: 0.26 to 1.65) and involved serum FLC ≥100 mg/L; Confirmed expression of the BCMA target antigen on MM cells by flow cytometry or bone marrow immunohistochemistry; Assessed by the investigator as transplant-eligible.
Exclusion: Concurrent amyloidosis; Previous treatment with BCMA-targeted therapy or CAR-T cell therapy; Primary plasma cell leukemia; Involvement of the central nervous system (CNS).